Essa Pharma Inc EPIX

NAS: EPIX | ISIN: CA29668H7085   14/11/2024
1,760 USD (-0,56%)
(-0,56%)   14/11/2024

ESSA Pharma to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London.

David. R. Parkinson, President, and Chief Executive Officer; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.

A live webcast of the Jefferies presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com, and follow us on Twitter and LinkedIn.

Contacts

ESSA Pharma, Inc.
Peter Virsik
Chief Operating Officer
778.331.0962
pvirsik@essapharma.com

Investors and Media:
Argot Partners
212.600.1902
essa@argotpartners.com 

Cision View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-present-at-the-jefferies-london-healthcare-conference-301980837.html

SOURCE ESSA Pharma Inc

Mijn selecties